HLA Protein (www.hlaprotein.com) was formed by Pure Protein, L.L.C., an HLA company that has developed comprehensive analytical capabilities in the field of human leukocyte antigen (HLA) immunology and an approach to produce soluble forms of the HLA molecule (sHLA). Our website www.hlaprotein.com offers academic and commercial research groups individual HLA reagents to detect, profile, and monitor allele-specific immune responses from antibodies to immune cell populations. Furthermore, we also offer HLA peptide epitope binding services to help design improved vaccination and therapeutic targeting strategies. For over 20 years, Pure Protein has provided technology and expertise to advance novel therapies and diagnostic tools for applications in oncology, autoimmunity, infectious disease and antibody mediated graft rejection in transplantation. We now offering 126 Class I and 154 Class II proteins in both unmodified and biotinylated forms. These HLA Class I and II proteins properly present antigenic regions and are created in an industrialized and standardized process that delivers naturally folded, endogenously loaded, recombinant molecules that lack the transmembrane domain, synthesized in mammalian cells and purified to the highest degree using affinity chromatography. www.hlaprotein.com services include: 1) Validation of individual peptide epitope candidates using assays that directly measure accurate IC50 values to allow the proper prioritization of their immunogenic potential; 2) Screening of focused peptide libraries to identify the highest ranking, potentially immunogenic epitopes while simultaneously eliminating non-binders, effectively accelerating the discovery process and reducing cost. 3) T cell epitope mapping to discover immunotherapy targets utilizing a high-throughput approach to create individual epitope maps on any chosen protein potentially recognized by T cells.